Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Grapefruit Benefits

NeurogesX Provides U.S. Regulatory Update For Qutenza(TM)
NeurogesX, Inc. (Nasdaq: NGSX) announced that the U.S. Food and Drug Administration (FDA) agreed to its proposed study to evaluate Qutenza(TM) in patients with post-herpetic neuralgia (PHN) following pretreatment with an FDA-approved topical anesthetic. As part of its ongoing new drug application (NDA) review, the FDA wants to determine whether pretreatment with an FDA-approved topical anesthetic would provide similar tolerability to the topical agent used as a pretreatment in the clinical development program.
generic viagra online
Radiofrequency Ablation Durable After 2 Years, Compares Favorably With Endoscopic Resection For Advanced Disease, Reduces Risk For Cancer Progression
Results from a number of clinical trials were presented during the Digestive Disease Week (DDW) in Chicago this week, revealing new outcomes data related to endoscopic radiofrequency ablation using the HALO ablation system for eradicating a pre-cancerous esophageal condition known as Barrett"s esophagus. Among them, reports included durability outcomes from a randomized sham-controlled trial, safety and efficacy outcomes from a large U.S. registry of 429 patients, a randomized trial comparing ablation to endoscopic resection, and the largest European series to date in patients with high-grade dysplasia and early cancer.
News of the day
Potential Diabetes Cure Following Discovery Of Genetic Toggle Switch
Scientists have identified a master regulator gene for early embryonic development of the pancreas and other organs, putting researchers closer to coaxing stem cells into pancreatic cells as a possible cure for type1 diabetes.
Mental Health

Teva Announces Approval And Launch Of Generic Urso 250(R) And Urso Forte(R)

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration has granted approval for the Company"s Abbreviated New Drug Application (ANDA) for Ursodiol Tablets USP, 250 mg and 500 mg. Teva"s Ursodiol Tablets are the AB-rated generic equivalents of Axcan"s Urso 250® and Urso Forte®, which are indicated for treatment of patients with primary biliary cirrhosis. Shipment of this product has commenced. The brand product had annual sales of approximately $76 million in the United States for the twelve months that ended March 31, 2009, based on IMS sales data. Teva Pharmaceutical Industries Ltd


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009